Enzon Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OQB
Icahn-affiliated entities increased their beneficial ownership in Viskase Holdings to 93.7% following the completion of the Viskase Companies merger and a preferred stock exchange.
OQB
Icahn Enterprises affiliates have provided written consent to the merger and certificate of incorporation amendment for Enzon Pharmaceuticals, Inc.
OQB
Enzon Pharmaceuticals and Viskase amend their merger agreement, adjusting ownership stakes, extending the deadline, and securing continued support from Icahn Enterprises.
OQB
SCHEDULE 13D/A: Enzon Pharmaceuticals to Merge with Viskase, Forming Viskase Holdings, Inc. Under Icahn Control
Enzon Pharmaceuticals, Inc. announced a definitive merger agreement with Viskase Companies, Inc., a transaction expected to result in Icahn Enterprises Holdings L.P. beneficially owning approximately 91% of the combined entity, Viskase Holdings, Inc.